Developer of a biomaterials development platform designed to create biodegradable fibers with tailored aesthetic and performance properties. The company's platform designs fibers at the DNA level for sustainable textiles with inherent properties such as color, moisture management and stretch, enabling the fashion industry to design apparel without adversely impacting the environment.
Developer of antibody-based therapeutics intended to provide a new approach to treating fibrosis. The company engages in the development of therapeutics that target key fibrotic mediator proteins that aid in the development of fibrosis in chronically damaged organs, enabling medical practitioners to halt and reverse critical fibrosis and associated conditions.
Inspirna is a biopharmaceutical company focused on discovering and developing innovative therapeutic targets and drugs for various cancer subtypes, including melanoma, colorectal cancer, and triple-negative breast cancer. Utilizing a proprietary microRNA-based target discovery platform, Inspirna identifies and validates novel post-transcriptionally regulated targets, leading to the creation of first-in-class therapeutics. The company has developed several promising drug candidates, such as RGX-104, an oral small molecule designed for treating solid tumors, RGX-202, which targets cancer metabolism in gastrointestinal cancers, and RGX-019, a monoclonal antibody aimed at disrupting pathways that promote tumor progression and metastasis. Founded in 2010 and headquartered in New York, Inspirna strives to transform the lives of cancer patients by providing safe and effective therapies for metastatic disease.
Biosyntia ApS is a biotechnology company based in Hørsholm, Denmark, founded in 2012. The company specializes in developing biocatalysts for the fermentation of complex chemical compounds, such as flavors, fragrances, active pharmaceutical ingredients (APIs), pigments, and additives. Utilizing its innovative, patent-pending high-throughput screening technology, Biosyntia accelerates the development of these biocatalysts, aiming to enhance efficiency and reduce production costs. By focusing on biocatalysis, the company offers a more sustainable alternative to traditional chemical synthesis, significantly lowering environmental impacts. Biosyntia collaborates with manufacturers to create tailored fermentation processes that promote greener manufacturing practices in the fine chemicals industry.
Micropep Technologies is an agricultural biotechnology company founded in 2016 and based in Toulouse, France. The company specializes in the development of non-GMO bioherbicides and biostimulants, leveraging its proprietary miPEP technology, which utilizes naturally-occurring micro-peptides to manipulate gene expression in plants while preserving their DNA. This innovative approach enables the regulation of various growth processes, including germination, flowering, and overall plant growth, as well as effective weed control. By focusing on the use of natural molecules, Micropep aims to provide sustainable solutions for agricultural challenges.
GFBiochemicals is the only company to produce levulinic acid at commercial scale directly from biomass. In 2008, a group of biobased chemical experts saw the significant potential of levulinic acid to replace petroleum-based products across a range of market sectors. GFBiochemicals was founded to develop the production technology needed for this revolution in chemicals and biofuels. GFBiochemicals demonstrated these breakthrough technologies in the Caserta plant, in partnership with the University of Pisa and the Polytechnic University of Milan. This commercial-scale plant was retrofitted with new conversion, recovery and purification technology.
Elicit Plant is an agro-biotech company focused on enhancing the water resistance of crops and developing innovative phytosterol-based solutions. The company aims to facilitate the ecological transition in agriculture by addressing global challenges posed by climate change, particularly its impact on major crops. Elicit Plant utilizes proprietary technology that leverages phytosterols to improve plant stress resistance and activate natural defenses. Extensive field trials conducted across three continents have shown that these biosolutions are a viable option for farmers, offering consistent and significant returns on investment.
Meiogenix SAS is a biotechnology company based in Paris, France, that specializes in developing breeding and genomic technologies aimed at unlocking the unexplored genetic diversity of organisms. Established in 2010, Meiogenix offers innovative solutions such as SpiX technology, which enhances homologous recombination in specific regions of the genome, and PhoeniX, a non-genetically modified method that facilitates meiotic recombination in hybrid diploid or polyploid yeast cells. These advancements enable the company to support the development of new products that address pressing global food and industrial challenges, expanding natural biodiversity through natural breeding techniques.
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.
Synthace Limited is a company that develops software and processes aimed at enhancing productivity in biosciences across various industries, including health, pharmaceuticals, food, energy, agri-science, and manufacturing. Central to its offerings is Antha, a cloud-based platform designed to automate and improve biological processes. Antha allows users to visually design, execute, and analyze biological workflows, linking lab equipment, protocols, and processes to enable repeatable and efficient development. Founded in 2011 and headquartered in London, with an additional location in Cambridge, Massachusetts, Synthace also maintains a strategic partnership with Microsoft to further its mission of increasing bioscience productivity and facilitating better engineering of biological systems.
Home Biosciences is a European venture builder focused on the biotechnology sector. The company aims to facilitate scientific breakthroughs by employing an asset-centric operating model. It provides essential funding and operational support, allowing project teams to concentrate on their core objectives. By assembling the appropriate expertise and structure, Home Biosciences helps to foster the growth of sustainable biotech ventures.
Nitrase Therapeutics is a biopharmaceutical company focused on discovering and developing drugs targeting a newly identified class of enzymes known as Nitrases. Initially concentrating on Parkinson’s disease, Nitrase aims to create therapies that may slow or halt the progression of this neurodegenerative condition. Beyond its primary focus, the company plans to expand its research to address other aging-related diseases, including Type II diabetes, heart disease, and various cancer types. Founded in 2012 and headquartered in Jackson, Wyoming, with additional facilities in San Francisco, California, Nitrase Therapeutics is positioned to contribute significantly to the treatment of complex diseases associated with aging.
Sphere Fluidics Limited is a life sciences company focused on developing innovative technologies for single-cell analysis and characterization. The company offers specialized cell analysis systems that facilitate the discovery of new cell strains and molecules, aiding scientists in screening for and isolating rare biological variants. Their products serve various applications, including research, therapeutic development, bioproduction, and diagnostics. By providing collaborative research and development services, Sphere Fluidics aims to help clients enhance efficiency, reduce costs, and accelerate advancements in biological and biopharmaceutical discovery.
Operater of a cell therapy company intended to develop novel cell therapies for patients with solid tumors and no treatment options. The company specializes in the development of CAR T-cell therapies that produce a better and more durable response than previous CAR T generations, enabling healthcare professionals to improve treatment outcomes and save the lives of patients with refractory cancers.
iOmx Therapeutics AG is a Munich-based company specializing in immuno-oncology target discovery and drug development. The company focuses on creating innovative cancer therapeutics that target novel immune checkpoint modulators present on tumor cells. By employing a systematic screening approach of human tumor cells, iOmx has identified several new targets and studied their mechanisms of action. The foundation of its research is based on the principles of cancer immune-checkpoint therapy, which aims to overcome the natural resistance of tumors to immune responses. This resistance is often facilitated by cell surface molecules that activate immune-inhibitory receptors on T cells. By neutralizing these inhibitory interactions, iOmx Therapeutics seeks to reactivate the host immune response, thereby enhancing the effectiveness of cancer treatments.
Protera Biosciences, Inc. specializes in the production of protein-based food ingredients, focusing on innovative solutions to enhance food quality and safety. Founded in 2015 and located in Sunnyvale, California, the company offers a range of products including Protera Guard, a clean label protein that extends shelf life and replaces chemical preservatives, and Protera Sense, a plant-based oil that improves food texture without the use of palm oil or trans fats. Additionally, Protera provides antioxidant proteins and foaming and emulsifying proteins suitable for various applications, such as bakery products, chocolate, ice cream, and plant-based meat alternatives. Utilizing a proprietary deep learning algorithm named MADI, Protera accelerates the design and development of high-value protein products and enzymes, allowing for rapid validation and collaboration with clients to scale production effectively while addressing ethical and environmental challenges in food manufacturing.
Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer treatments that target DNA damage response (DDR) pathways. Founded in 2015, the company aims to create first-in-class therapies that selectively kill cancer cells by exploiting the mechanisms involved in DNA repair. Its product pipeline features several promising candidates, including DNA polymerase theta (Polθ) and an in-licensed program targeting a novel DDR protein. Artios collaborates with Cancer Research Technology and leading researchers in the field to advance its development efforts. The company's leadership comprises experts with extensive experience in DDR drug discovery, and it has garnered investment from notable entities, including SV Life Sciences and AbbVie Ventures.
Comet Biorefining, Inc. is based in London, Canada, and specializes in the development of sustainable ingredients from agricultural waste materials. The company focuses on converting non-food sources such as wood, wheat straw, bagasse, and corn stover into high-purity cellulosic glucose syrup. This innovative technology provides a cost-competitive alternative to traditional food-based sugar sources like corn or sugar cane, ensuring price stability and lower costs. In addition to its glucose products, Comet Biorefining offers biomass conversion and pretreatment services, along with a range of consulting services that include process development, engineering, and project development. The company is currently focused on scaling up its commercial operations and establishing partnerships within the renewable biofuels and biochemicals industries.
Operator of a biopharmaceutical company intended to discover and develop therapies that slow or stop the progression of neurodegenerative diseases. The company engages in identifying new medicines to preserve cognition and other brain functions and enhance resilience to neurodegenerative diseases including Alzheimer's, Frontotemporal Dementia, and Parkinson's, enabling people suffering from neurodegenerative diseases to access suitable therapeutics for fast recovery.
Micropep Technologies is an agricultural biotechnology company founded in 2016 and based in Toulouse, France. The company specializes in the development of non-GMO bioherbicides and biostimulants, leveraging its proprietary miPEP technology, which utilizes naturally-occurring micro-peptides to manipulate gene expression in plants while preserving their DNA. This innovative approach enables the regulation of various growth processes, including germination, flowering, and overall plant growth, as well as effective weed control. By focusing on the use of natural molecules, Micropep aims to provide sustainable solutions for agricultural challenges.
Protera Biosciences, Inc. specializes in the production of protein-based food ingredients, focusing on innovative solutions to enhance food quality and safety. Founded in 2015 and located in Sunnyvale, California, the company offers a range of products including Protera Guard, a clean label protein that extends shelf life and replaces chemical preservatives, and Protera Sense, a plant-based oil that improves food texture without the use of palm oil or trans fats. Additionally, Protera provides antioxidant proteins and foaming and emulsifying proteins suitable for various applications, such as bakery products, chocolate, ice cream, and plant-based meat alternatives. Utilizing a proprietary deep learning algorithm named MADI, Protera accelerates the design and development of high-value protein products and enzymes, allowing for rapid validation and collaboration with clients to scale production effectively while addressing ethical and environmental challenges in food manufacturing.
Alia Therapeutics is developing next-generation gene-editing medicines to cure rare genetic diseases.
AAVantgarde Bio is focused on developing innovative gene therapies specifically for inherited retinal disorders. The company utilizes proprietary Adeno-Associated Viral (AAV) vector platforms to overcome the limitations associated with the cargo capacity of traditional AAV vectors. This technology allows for the delivery of larger genes to both ocular and non-ocular tissues, enhancing the potential for effective treatment in patients. By addressing these challenges, AAVantgarde Bio aims to advance the field of gene therapy and improve outcomes for individuals affected by genetic eye diseases.
Borea Therapeutics is advancing a new generation of gene therapies that would enable the targeting of specific tissues and cells.
Operator of a drug discovery platform designed to develop immune based therapies, including powerful cell therapies, that create accessible cures for solid tumors and blood cancers. The company's platform offers leveraging epigenetic variation and CAR-T precision genetic engineering technology to target tumorous epitopes that are broadly represented across various cancers, enabling patients to get allogeneic treatments to overcome disease.
Catamaran Bio, Inc. develops CAR-NK immune cell therapies for the treatment of tumor. The company develops Tailwind platform to engineer, expand, and process NK cells into allogenic CAR-NK cell therapy shelf products. Catamaran Bio, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.
Myricx Bio is a drug discovery company based in Stevenage, United Kingdom, that specializes in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT). Founded in 2019, the company focuses primarily on oncology while also exploring applications in other diseases such as inflammatory conditions, epilepsy, and Alzheimer’s disease. By targeting N-myristoyl transferase, Myricx Bio aims to unlock new therapeutic potentials, providing precision medicines that can specifically kill cancer cells and address viral infections. Through its innovative approach, the company seeks to deliver effective treatments for a diverse range of health conditions.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, specializing in the discovery and development of gene therapy treatments for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. The company utilizes two primary technology platforms: mitochondrial targeting sequences and optogenetics, aiming to preserve or restore vision in patients affected by severe retinal diseases. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III clinical trials for treating Leber hereditary optic neuropathy associated with ND4 gene mutations, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. Additionally, GenSight is advancing various preclinical programs targeting both ophthalmic and neurodegenerative conditions, reflecting its commitment to innovative solutions for patients with significant vision impairment or blindness. GenSight Biologics was founded in 2012.
Polyneuron Pharmaceuticals AG is focused on developing innovative therapeutics for the treatment of antibody-mediated autoimmune disorders. The company is working on several drug candidates, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron utilizes a platform technology called Antibody-Catch, which is based on biodegradable glycopolymers. This technology selectively targets and eliminates pathological autoantibodies while preserving the integrity of the rest of the immune system. Founded in 2014 and headquartered in Basel, Switzerland, Polyneuron aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system.
Enthera S.r.l. is an Italian biotechnology company established in 2016, based in Milan, and operates as a subsidiary of BiovelocITA S.r.l. The company focuses on developing innovative biologics aimed at treating diabetes and its related gastrointestinal complications, particularly enteropathy, as well as other intestinal disorders that share similar biological pathways. Enthera's research is centered on monoclonal antibody discovery and biotherapeutics that target mechanisms involved in cell apoptosis in the gut, pancreas, and other organs. By addressing these pathways, Enthera aims to provide effective treatments for underserved autoimmune conditions, thereby contributing to advancements in the management of type 1 diabetes and inflammatory bowel disease. The company's name reflects its mission, combining the terms "entero," relating to the intestine, and "therapy."
MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.
Protera Biosciences, Inc. specializes in the production of protein-based food ingredients, focusing on innovative solutions to enhance food quality and safety. Founded in 2015 and located in Sunnyvale, California, the company offers a range of products including Protera Guard, a clean label protein that extends shelf life and replaces chemical preservatives, and Protera Sense, a plant-based oil that improves food texture without the use of palm oil or trans fats. Additionally, Protera provides antioxidant proteins and foaming and emulsifying proteins suitable for various applications, such as bakery products, chocolate, ice cream, and plant-based meat alternatives. Utilizing a proprietary deep learning algorithm named MADI, Protera accelerates the design and development of high-value protein products and enzymes, allowing for rapid validation and collaboration with clients to scale production effectively while addressing ethical and environmental challenges in food manufacturing.
NodThera Limited is a biotechnology company focused on researching and developing novel inhibitors of the NLRP3 inflammasome, which play a critical role in inflammatory and neuroinflammatory diseases. Established in 2016 and headquartered in Little Chesterford, United Kingdom, NodThera operates a laboratory in Seattle, Washington, and a corporate office in Lexington, Massachusetts. The company aims to create therapies targeting a range of conditions including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. By developing potent and selective NLRP3 inflammasome inhibitors, NodThera seeks to reduce pro-inflammatory cytokines, enabling more effective treatment options for patients suffering from chronic inflammation-related diseases.
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.
PinCell is a biotech company focused on the research of therapeutic molecules based on new targets related to the pathomechanisms of inflammatory and neoplastic skin diseases.
Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases.
Epsilen Bio Srl is a Milan-based biotechnology company focused on developing innovative therapies for patients with underserved medical conditions. Founded in December 2019, the company specializes in a transformative approach known as epigenetic silencing, which targets and stabilizes the genomic silencing of genes implicated in various pathological processes. By leveraging this platform, Epsilen Bio aims to provide healthcare professionals with new therapeutic options to address significant medical needs.
Nitrase Therapeutics is a biopharmaceutical company focused on discovering and developing drugs targeting a newly identified class of enzymes known as Nitrases. Initially concentrating on Parkinson’s disease, Nitrase aims to create therapies that may slow or halt the progression of this neurodegenerative condition. Beyond its primary focus, the company plans to expand its research to address other aging-related diseases, including Type II diabetes, heart disease, and various cancer types. Founded in 2012 and headquartered in Jackson, Wyoming, with additional facilities in San Francisco, California, Nitrase Therapeutics is positioned to contribute significantly to the treatment of complex diseases associated with aging.
EnginZyme AB is a biotechnology company based in Stockholm, Sweden, founded in 2014. It specializes in biocatalysis and offers a cell-free synthetic biology platform that aims to provide sustainable alternatives to traditional fossil-based materials such as plastics, nylons, and rubbers. EnginZyme's technology facilitates the use of enzymes in standard chemical processing equipment, allowing for efficient and cost-effective biomanufacturing at an industrial scale. The company's mission is to promote the adoption of biocatalysis as a primary method for chemical process design, thereby supporting the transition of the chemical industry towards more sustainable practices. EnginZyme serves various sectors, including pharmaceuticals, food, chemicals, and flavors and fragrances.
Inventiva S.A. is a biopharmaceutical company based in Daix, France, specializing in the development of oral small molecule therapies targeting significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company's lead candidate, Lanifibranor, is currently in Phase IIb clinical trials for the treatment of nonalcoholic steatohepatitis. Additionally, Inventiva is advancing Odiparcil, in Phase IIa trials for mucopolysaccharidosis type VI, and has several preclinical programs, including potential treatments for malignant mesothelioma and lung cancer. The company's research and development efforts are supported by a proprietary library of molecules and a team experienced in targeting nuclear receptors and transcription factors. Inventiva has established partnerships with prominent organizations, including the Institut Curie for oncology research and AbbVie for autoimmune disease treatments. Founded in 2011, the company continues to focus on innovative solutions for complex medical conditions.
Chroma Medicine is a genomic medicine company focused on epigenetic editing to transform the treatment of genetically driven diseases. By leveraging epigenetics, which regulates gene expression naturally, Chroma Medicine aims to develop innovative therapies that provide precise control over gene activity. The company utilizes programmable epigenetic editors that combine DNA binding domains with epigenetic effector domains, allowing for targeted manipulation of genes and chromatin structure. This approach promises to create a new class of therapeutics that offers unparalleled control over gene expression, potentially leading to more effective treatments for a range of genetic disorders.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, specializing in the discovery and development of gene therapy treatments for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. The company utilizes two primary technology platforms: mitochondrial targeting sequences and optogenetics, aiming to preserve or restore vision in patients affected by severe retinal diseases. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III clinical trials for treating Leber hereditary optic neuropathy associated with ND4 gene mutations, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. Additionally, GenSight is advancing various preclinical programs targeting both ophthalmic and neurodegenerative conditions, reflecting its commitment to innovative solutions for patients with significant vision impairment or blindness. GenSight Biologics was founded in 2012.
DMC Biotechnologies, Inc. is a biotechnology company based in Boulder, Colorado, focused on developing bio-based products through microbial fermentation technology. The company specializes in the production of specialty chemicals, flavors, fragrances, nutraceuticals, and pharmaceuticals. By utilizing Dynamic Metabolic Control technology, DMC aims to streamline the production process, reducing both costs and development timelines from discovery to commercial viability. Founded in 2014, DMC Biotechnologies is dedicated to creating sustainable manufacturing solutions that utilize lower energy and resources, contributing to a more sustainable economy.
Inventiva S.A. is a biopharmaceutical company based in Daix, France, specializing in the development of oral small molecule therapies targeting significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company's lead candidate, Lanifibranor, is currently in Phase IIb clinical trials for the treatment of nonalcoholic steatohepatitis. Additionally, Inventiva is advancing Odiparcil, in Phase IIa trials for mucopolysaccharidosis type VI, and has several preclinical programs, including potential treatments for malignant mesothelioma and lung cancer. The company's research and development efforts are supported by a proprietary library of molecules and a team experienced in targeting nuclear receptors and transcription factors. Inventiva has established partnerships with prominent organizations, including the Institut Curie for oncology research and AbbVie for autoimmune disease treatments. Founded in 2011, the company continues to focus on innovative solutions for complex medical conditions.
Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.
Biotalys is a green biotech company that employs its proprietary Agrobody technology platform to develop crop protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combine the high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications. It was incorporated in 2012 and is based in Ghent, Belgium.
Comet Biorefining, Inc. is based in London, Canada, and specializes in the development of sustainable ingredients from agricultural waste materials. The company focuses on converting non-food sources such as wood, wheat straw, bagasse, and corn stover into high-purity cellulosic glucose syrup. This innovative technology provides a cost-competitive alternative to traditional food-based sugar sources like corn or sugar cane, ensuring price stability and lower costs. In addition to its glucose products, Comet Biorefining offers biomass conversion and pretreatment services, along with a range of consulting services that include process development, engineering, and project development. The company is currently focused on scaling up its commercial operations and establishing partnerships within the renewable biofuels and biochemicals industries.
Abivax is a clinical-stage biotechnology company based in Paris, France, dedicated to discovering and optimizing treatments for inflammatory diseases, viral infections, and cancer. The company is primarily focused on its lead product, ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis and Crohn’s Disease, as well as for COVID-19. Additionally, ABX464 is being evaluated in Phase IIa trials for rheumatoid arthritis and has completed Phase IIa trials aimed at achieving viral remission in HIV patients. Abivax is also developing ABX 196, an immune enhancer in Phase 1/2 trials for hepatocellular cancer, and ABX 544, a candidate for Ebola treatment based on polyclonal antibodies. Furthermore, the company is conducting research into treatments for Dengue fever, influenza, and respiratory syncytial virus. Abivax collaborates with institutions such as the French National Centre for Scientific Research and the University of Montpellier. Founded in 2013, the company aims to harness the body’s immune response to manage chronic inflammatory conditions effectively.
Microphyt, founded in 2007 and headquartered in Baillargues, France, specializes in the research, development, production, and marketing of natural algae-based products. The company focuses on microalgae and other photosynthetic microorganisms, targeting sectors such as beauty care, food, health, and energy. Its offerings include dietary supplements and products aimed at promoting weight loss and enhancing brain health. Utilizing industrial-scale cultivation techniques, Microphyt preserves the integrity of microalgae cells to produce biomass and extracts in commercial quantities. This approach enables the healthcare industry to meet the growing demand for innovative personal care and food products.
Comet Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. It specializes in developing novel small-molecule treatments targeting various diseases, particularly orphan neurological disorders. The company's core innovation is its CoEnzyme metabolism platform, which aims to restore dysregulated CoEnzyme A metabolism. This therapeutic approach enables healthcare providers to address significant unmet medical needs in the treatment of these complex conditions.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
Twentyeight-Seven, Inc. is a biotechnology company based in Watertown, Massachusetts, specializing in the development of small molecules that modulate microRNAs (miRNAs) by targeting the proteins that interact with these molecules. Their innovative approach focuses on using short non-coding RNAs to inhibit gene expression, suppress mRNA translation, and promote mRNA decay. By targeting miRNAs that play a critical role in cancer initiation, progression, and metastasis, Twentyeight-Seven aims to create effective therapeutic solutions for cancer treatment.
Polyneuron Pharmaceuticals AG is focused on developing innovative therapeutics for the treatment of antibody-mediated autoimmune disorders. The company is working on several drug candidates, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron utilizes a platform technology called Antibody-Catch, which is based on biodegradable glycopolymers. This technology selectively targets and eliminates pathological autoantibodies while preserving the integrity of the rest of the immune system. Founded in 2014 and headquartered in Basel, Switzerland, Polyneuron aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, specializing in the discovery and development of gene therapy treatments for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. The company utilizes two primary technology platforms: mitochondrial targeting sequences and optogenetics, aiming to preserve or restore vision in patients affected by severe retinal diseases. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III clinical trials for treating Leber hereditary optic neuropathy associated with ND4 gene mutations, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. Additionally, GenSight is advancing various preclinical programs targeting both ophthalmic and neurodegenerative conditions, reflecting its commitment to innovative solutions for patients with significant vision impairment or blindness. GenSight Biologics was founded in 2012.
Afyren is a sustainable chemistry company based in Saint-Beauzire, France, focused on the valorization of non-food biomass to develop environmentally friendly alternatives to petroleum-based products. Founded in 2012, the company employs innovative biotechnological processes using natural microorganisms to produce a range of bio-sourced organic acids and a high-value fertilizer. Its services extend to microbiology and bioprocess engineering, supporting various sectors including pharmaceuticals, cosmetics, green chemistry, and biopolymers. Afyren's approach aligns with the principles of a circular, low-carbon economy, emphasizing the importance of waste reduction and sustainable resource utilization.
Checkmate Pharmaceuticals is a clinical-stage biotechnology company based in Cambridge, Massachusetts, that specializes in developing novel immunotherapies for cancer treatment. Founded in 2015, the company focuses on leveraging CpG oligonucleotides to enhance anti-tumor T-cell responses and overcome the mechanisms that allow tumors to evade immune detection. By combining its proprietary technology with checkpoint inhibition, Checkmate aims to improve the efficacy of existing immunotherapies and provide new treatment options for patients. The company has formed strategic alliances with major pharmaceutical firms, including Merck KGaA and Pfizer, to further its research and development efforts in the field of cancer immunotherapy.
Inspirna is a biopharmaceutical company focused on discovering and developing innovative therapeutic targets and drugs for various cancer subtypes, including melanoma, colorectal cancer, and triple-negative breast cancer. Utilizing a proprietary microRNA-based target discovery platform, Inspirna identifies and validates novel post-transcriptionally regulated targets, leading to the creation of first-in-class therapeutics. The company has developed several promising drug candidates, such as RGX-104, an oral small molecule designed for treating solid tumors, RGX-202, which targets cancer metabolism in gastrointestinal cancers, and RGX-019, a monoclonal antibody aimed at disrupting pathways that promote tumor progression and metastasis. Founded in 2010 and headquartered in New York, Inspirna strives to transform the lives of cancer patients by providing safe and effective therapies for metastatic disease.
Enthera S.r.l. is an Italian biotechnology company established in 2016, based in Milan, and operates as a subsidiary of BiovelocITA S.r.l. The company focuses on developing innovative biologics aimed at treating diabetes and its related gastrointestinal complications, particularly enteropathy, as well as other intestinal disorders that share similar biological pathways. Enthera's research is centered on monoclonal antibody discovery and biotherapeutics that target mechanisms involved in cell apoptosis in the gut, pancreas, and other organs. By addressing these pathways, Enthera aims to provide effective treatments for underserved autoimmune conditions, thereby contributing to advancements in the management of type 1 diabetes and inflammatory bowel disease. The company's name reflects its mission, combining the terms "entero," relating to the intestine, and "therapy."
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.
NodThera Limited is a biotechnology company focused on researching and developing novel inhibitors of the NLRP3 inflammasome, which play a critical role in inflammatory and neuroinflammatory diseases. Established in 2016 and headquartered in Little Chesterford, United Kingdom, NodThera operates a laboratory in Seattle, Washington, and a corporate office in Lexington, Massachusetts. The company aims to create therapies targeting a range of conditions including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. By developing potent and selective NLRP3 inflammasome inhibitors, NodThera seeks to reduce pro-inflammatory cytokines, enabling more effective treatment options for patients suffering from chronic inflammation-related diseases.
Castle Biosciences, we focus on addressing this gap. We work with leading cancer institutions to in-license proprietary technologies and complete development and validation. The ultimate goal is to make these proven tests available to all individuals afflicted with a rare cancer.
Biosyntia ApS is a biotechnology company based in Hørsholm, Denmark, founded in 2012. The company specializes in developing biocatalysts for the fermentation of complex chemical compounds, such as flavors, fragrances, active pharmaceutical ingredients (APIs), pigments, and additives. Utilizing its innovative, patent-pending high-throughput screening technology, Biosyntia accelerates the development of these biocatalysts, aiming to enhance efficiency and reduce production costs. By focusing on biocatalysis, the company offers a more sustainable alternative to traditional chemical synthesis, significantly lowering environmental impacts. Biosyntia collaborates with manufacturers to create tailored fermentation processes that promote greener manufacturing practices in the fine chemicals industry.
Crescendo Biologics Limited is a Cambridge-based company focused on developing innovative therapies for oncology and dermatology, particularly through small molecules and monoclonal antibodies. The company specializes in multi-specific immune-oncology modulators and Humabody Drug Conjugates, leveraging a proprietary transgenic mouse platform that facilitates the in vivo maturation of human VH domains. This technology allows Crescendo to optimize the affinity and biophysical properties of its Humabodies, which are small antibody fragments retaining essential binding capabilities. By addressing challenges in generating high-affinity, soluble human VH antibody fragments, Crescendo aims to develop potent, multi-functional therapeutics. The company engages in both in-house product development and partnerships with other organizations to expand its impact in the field of antibody therapeutics. Established in 2007, Crescendo Biologics was originally named Translocus Limited before rebranding in 2009.
EryDel S.p.A., based in Urbino, Italy, specializes in the production and commercialization of innovative drug delivery systems utilizing autologous erythrocytes, or red blood cells. Founded in 2007, the company has developed patented technology that allows for the efficient loading of red blood cells with various therapeutic agents, including drugs and proteins. This approach enables a gradual release of these agents into the patient's body, enhancing treatment efficacy while minimizing side effects. The technology is particularly beneficial for managing chronic conditions, offering a potential alternative to daily treatments through monthly transfusions of specially loaded blood. EryDel's offerings include a red cell loader and disposable kits to support the drug delivery process. The company's solutions have been tested in treating Inflammatory Bowel Diseases (IBDs) such as ulcerative colitis and Crohn's disease, and it aims to improve the management of other rare diseases through its innovative therapies.
Inventiva S.A. is a biopharmaceutical company based in Daix, France, specializing in the development of oral small molecule therapies targeting significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company's lead candidate, Lanifibranor, is currently in Phase IIb clinical trials for the treatment of nonalcoholic steatohepatitis. Additionally, Inventiva is advancing Odiparcil, in Phase IIa trials for mucopolysaccharidosis type VI, and has several preclinical programs, including potential treatments for malignant mesothelioma and lung cancer. The company's research and development efforts are supported by a proprietary library of molecules and a team experienced in targeting nuclear receptors and transcription factors. Inventiva has established partnerships with prominent organizations, including the Institut Curie for oncology research and AbbVie for autoimmune disease treatments. Founded in 2011, the company continues to focus on innovative solutions for complex medical conditions.
EnobraQ is a start-up created in 2015, from a pre-competitive research project supported by Toulouse White Biotechnology (TWB). Concerned with ecological and economic considerations, EnobraQ develops breakthrough technologies that use CO2 and target markets as diverse as nutrition, agri-food, cosmetics, pharmacology and bioplastics.
Micropep Technologies is an agricultural biotechnology company founded in 2016 and based in Toulouse, France. The company specializes in the development of non-GMO bioherbicides and biostimulants, leveraging its proprietary miPEP technology, which utilizes naturally-occurring micro-peptides to manipulate gene expression in plants while preserving their DNA. This innovative approach enables the regulation of various growth processes, including germination, flowering, and overall plant growth, as well as effective weed control. By focusing on the use of natural molecules, Micropep aims to provide sustainable solutions for agricultural challenges.
Synthace Limited is a company that develops software and processes aimed at enhancing productivity in biosciences across various industries, including health, pharmaceuticals, food, energy, agri-science, and manufacturing. Central to its offerings is Antha, a cloud-based platform designed to automate and improve biological processes. Antha allows users to visually design, execute, and analyze biological workflows, linking lab equipment, protocols, and processes to enable repeatable and efficient development. Founded in 2011 and headquartered in London, with an additional location in Cambridge, Massachusetts, Synthace also maintains a strategic partnership with Microsoft to further its mission of increasing bioscience productivity and facilitating better engineering of biological systems.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
Biotalys is a green biotech company that employs its proprietary Agrobody technology platform to develop crop protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combine the high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications. It was incorporated in 2012 and is based in Ghent, Belgium.
Breath Therapeutics GmbH, based in Munich, Germany, with an additional office in Menlo Park, California, develops innovative drug-aerosol therapeutics aimed at treating bronchiolitis obliterans syndrome and other severe respiratory diseases. Founded in 2016 and now a subsidiary of Zambon S.p.A., the company focuses on combining novel formulations of existing drugs with advanced inhalation technologies. Their products include a liposomal formulation of cyclosporine A designed for inhalation, paired with a high-performance nebulizer that optimizes drug delivery. This approach allows for rapid delivery of high drug concentrations directly to the lungs, enhancing the efficacy of treatments while reducing systemic exposure. Breath Therapeutics aims to address significant unmet medical needs in rare pulmonary conditions through its targeted inhalation therapies.
Comet Biorefining, Inc. is based in London, Canada, and specializes in the development of sustainable ingredients from agricultural waste materials. The company focuses on converting non-food sources such as wood, wheat straw, bagasse, and corn stover into high-purity cellulosic glucose syrup. This innovative technology provides a cost-competitive alternative to traditional food-based sugar sources like corn or sugar cane, ensuring price stability and lower costs. In addition to its glucose products, Comet Biorefining offers biomass conversion and pretreatment services, along with a range of consulting services that include process development, engineering, and project development. The company is currently focused on scaling up its commercial operations and establishing partnerships within the renewable biofuels and biochemicals industries.
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.
myTomorrows is a healthcare information platform that facilitates access to innovative drugs in development for patients and physicians who are often excluded from clinical trials. The company focuses on areas with significant unmet medical needs, including oncology, neurology, psychiatry, and rare diseases. By identifying promising treatments and gathering relevant information, myTomorrows informs both patients and healthcare providers about available drug options. The platform enables users to request access to these innovative therapies, thereby improving the chances for patients to receive potentially life-saving treatments that are otherwise difficult to obtain.
iOmx Therapeutics AG is a Munich-based company specializing in immuno-oncology target discovery and drug development. The company focuses on creating innovative cancer therapeutics that target novel immune checkpoint modulators present on tumor cells. By employing a systematic screening approach of human tumor cells, iOmx has identified several new targets and studied their mechanisms of action. The foundation of its research is based on the principles of cancer immune-checkpoint therapy, which aims to overcome the natural resistance of tumors to immune responses. This resistance is often facilitated by cell surface molecules that activate immune-inhibitory receptors on T cells. By neutralizing these inhibitory interactions, iOmx Therapeutics seeks to reactivate the host immune response, thereby enhancing the effectiveness of cancer treatments.
Delinia, Inc. is a biotechnology company based in San Francisco, California, dedicated to developing innovative therapeutics for autoimmune and inflammatory diseases. Founded in 2014, Delinia's primary focus is on a lead program that involves a molecule designed to selectively potentiate and expand regulatory T cells (Tregs), which play a vital role in maintaining self-tolerance and immune system balance. The company's scientific founders and experienced leadership team are committed to advancing its therapeutic programs toward clinical application. As of 2017, Delinia operates as a subsidiary of Celgene Corporation.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
Inspirna is a biopharmaceutical company focused on discovering and developing innovative therapeutic targets and drugs for various cancer subtypes, including melanoma, colorectal cancer, and triple-negative breast cancer. Utilizing a proprietary microRNA-based target discovery platform, Inspirna identifies and validates novel post-transcriptionally regulated targets, leading to the creation of first-in-class therapeutics. The company has developed several promising drug candidates, such as RGX-104, an oral small molecule designed for treating solid tumors, RGX-202, which targets cancer metabolism in gastrointestinal cancers, and RGX-019, a monoclonal antibody aimed at disrupting pathways that promote tumor progression and metastasis. Founded in 2010 and headquartered in New York, Inspirna strives to transform the lives of cancer patients by providing safe and effective therapies for metastatic disease.
MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.
Comet Biorefining, Inc. is based in London, Canada, and specializes in the development of sustainable ingredients from agricultural waste materials. The company focuses on converting non-food sources such as wood, wheat straw, bagasse, and corn stover into high-purity cellulosic glucose syrup. This innovative technology provides a cost-competitive alternative to traditional food-based sugar sources like corn or sugar cane, ensuring price stability and lower costs. In addition to its glucose products, Comet Biorefining offers biomass conversion and pretreatment services, along with a range of consulting services that include process development, engineering, and project development. The company is currently focused on scaling up its commercial operations and establishing partnerships within the renewable biofuels and biochemicals industries.
Synthace Limited is a company that develops software and processes aimed at enhancing productivity in biosciences across various industries, including health, pharmaceuticals, food, energy, agri-science, and manufacturing. Central to its offerings is Antha, a cloud-based platform designed to automate and improve biological processes. Antha allows users to visually design, execute, and analyze biological workflows, linking lab equipment, protocols, and processes to enable repeatable and efficient development. Founded in 2011 and headquartered in London, with an additional location in Cambridge, Massachusetts, Synthace also maintains a strategic partnership with Microsoft to further its mission of increasing bioscience productivity and facilitating better engineering of biological systems.
Green Biologics Limited is an industrial biotechnology company based in Abingdon, United Kingdom, focused on producing renewable specialty chemicals. The company offers products such as n-butanol, acetone, and C4 derivatives, along with GreenFlame charcoal lighting fluids. These products find applications in various sectors, including paints, coatings, adhesives, personal care, cosmetics, food ingredients, health, and industrial cleaners. Green Biologics aims to be a leader in advanced fermentation technologies that convert biomass into renewable fuels and chemicals. Established in 2002, the company has additional facilities in the United States and satellite offices in China, Brazil, and India.
myTomorrows is a healthcare information platform that facilitates access to innovative drugs in development for patients and physicians who are often excluded from clinical trials. The company focuses on areas with significant unmet medical needs, including oncology, neurology, psychiatry, and rare diseases. By identifying promising treatments and gathering relevant information, myTomorrows informs both patients and healthcare providers about available drug options. The platform enables users to request access to these innovative therapies, thereby improving the chances for patients to receive potentially life-saving treatments that are otherwise difficult to obtain.
Avantium is a technology company based in Amsterdam, specializing in advanced high-throughput research and development for the energy, chemicals, and pharmaceutical sectors. It employs proprietary technology that accelerates and reduces the costs associated with developing new products and processes. Avantium's innovative approach to experiment design and data analysis enhances its success rate in delivering effective solutions. The company has successfully collaborated with over 70 global clients, showcasing the commercial viability of its services. Avantium focuses on two primary areas: developing biofuels and bio-based chemicals, as well as new crystal forms of patented drugs. Its business model includes a strong emphasis on expanding its patent portfolio and establishing partnerships that add value. Additionally, Avantium operates through segments such as R&D Solutions, Renewable Chemistries, and Renewable Polymers, with the R&D Solutions segment generating the majority of its revenue. The company is supported by a team of experts in various fields, including catalysis, organic chemistry, and software development, who work closely with partner organizations to drive innovation in sustainable chemistry.
Crescendo Biologics Limited is a Cambridge-based company focused on developing innovative therapies for oncology and dermatology, particularly through small molecules and monoclonal antibodies. The company specializes in multi-specific immune-oncology modulators and Humabody Drug Conjugates, leveraging a proprietary transgenic mouse platform that facilitates the in vivo maturation of human VH domains. This technology allows Crescendo to optimize the affinity and biophysical properties of its Humabodies, which are small antibody fragments retaining essential binding capabilities. By addressing challenges in generating high-affinity, soluble human VH antibody fragments, Crescendo aims to develop potent, multi-functional therapeutics. The company engages in both in-house product development and partnerships with other organizations to expand its impact in the field of antibody therapeutics. Established in 2007, Crescendo Biologics was originally named Translocus Limited before rebranding in 2009.
ProQR Therapeutics N.V. is a biopharmaceutical company focused on the discovery and development of RNA-based therapeutics aimed at treating genetic disorders. The company is advancing several key product candidates, including sepofarsen, currently in a phase II/III trial for Leber’s congenital amaurosis type 10, and QR-421a, which is in a phase 1/2 trial for Usher syndrome type 2 and non-syndromic retinitis pigmentosa. Additionally, QR-1123 is in a phase 1/2 trial for autosomal dominant retinitis pigmentosa, while QR-504a is undergoing its first clinical trial for Fuchs endothelial corneal dystrophy. ProQR Therapeutics has established collaboration agreements with prominent institutions such as General Hospital Corporation and Radboud University Medical Center. Founded in 2012, the company is headquartered in Leiden, the Netherlands.
Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.
Crescendo Biologics Limited is a Cambridge-based company focused on developing innovative therapies for oncology and dermatology, particularly through small molecules and monoclonal antibodies. The company specializes in multi-specific immune-oncology modulators and Humabody Drug Conjugates, leveraging a proprietary transgenic mouse platform that facilitates the in vivo maturation of human VH domains. This technology allows Crescendo to optimize the affinity and biophysical properties of its Humabodies, which are small antibody fragments retaining essential binding capabilities. By addressing challenges in generating high-affinity, soluble human VH antibody fragments, Crescendo aims to develop potent, multi-functional therapeutics. The company engages in both in-house product development and partnerships with other organizations to expand its impact in the field of antibody therapeutics. Established in 2007, Crescendo Biologics was originally named Translocus Limited before rebranding in 2009.
Green Biologics Limited is an industrial biotechnology company based in Abingdon, United Kingdom, focused on producing renewable specialty chemicals. The company offers products such as n-butanol, acetone, and C4 derivatives, along with GreenFlame charcoal lighting fluids. These products find applications in various sectors, including paints, coatings, adhesives, personal care, cosmetics, food ingredients, health, and industrial cleaners. Green Biologics aims to be a leader in advanced fermentation technologies that convert biomass into renewable fuels and chemicals. Established in 2002, the company has additional facilities in the United States and satellite offices in China, Brazil, and India.
MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.
Synthace Limited is a company that develops software and processes aimed at enhancing productivity in biosciences across various industries, including health, pharmaceuticals, food, energy, agri-science, and manufacturing. Central to its offerings is Antha, a cloud-based platform designed to automate and improve biological processes. Antha allows users to visually design, execute, and analyze biological workflows, linking lab equipment, protocols, and processes to enable repeatable and efficient development. Founded in 2011 and headquartered in London, with an additional location in Cambridge, Massachusetts, Synthace also maintains a strategic partnership with Microsoft to further its mission of increasing bioscience productivity and facilitating better engineering of biological systems.
MetGen develops and produces enzymes tailored to industrial customer needs. MetZymes are enzymes belonging to the class of multicopper oxidases. These enzymes are involved in several oxidative functions and particularly in delignification.
MetGen have created biological enzymes that can be added into the pulp mix to separate wood fibres more effectively before the thermo-mechanical pulping stage, radically improving the energy efficiency of the whole pulp-making process.
MetGen develops and produces enzymes tailored to industrial customer needs. MetZymes are enzymes belonging to the class of multicopper oxidases. These enzymes are involved in several oxidative functions and particularly in delignification.
MetGen have created biological enzymes that can be added into the pulp mix to separate wood fibres more effectively before the thermo-mechanical pulping stage, radically improving the energy efficiency of the whole pulp-making process.
Entourage Medical Technologies
Venture Round in 2013
A stealth company that has not yet released what it focuses on.
ProQR Therapeutics N.V. is a biopharmaceutical company focused on the discovery and development of RNA-based therapeutics aimed at treating genetic disorders. The company is advancing several key product candidates, including sepofarsen, currently in a phase II/III trial for Leber’s congenital amaurosis type 10, and QR-421a, which is in a phase 1/2 trial for Usher syndrome type 2 and non-syndromic retinitis pigmentosa. Additionally, QR-1123 is in a phase 1/2 trial for autosomal dominant retinitis pigmentosa, while QR-504a is undergoing its first clinical trial for Fuchs endothelial corneal dystrophy. ProQR Therapeutics has established collaboration agreements with prominent institutions such as General Hospital Corporation and Radboud University Medical Center. Founded in 2012, the company is headquartered in Leiden, the Netherlands.
BioAmber is a private US company registered in the state of Delaware. The company, formerly known as DNP Green Technology, changed its name to BioAmber following its acquisition of its joint venture with ARD. Following the transaction, they adopted the name BioAmber, which had been used to that point by the joint venture.
Creabilis SA is a clinical stage biotechnology company based in Luxembourg City, specializing in the research and development of new drugs for dermatology and inflammatory diseases. Founded in 2003, the company has developed a diverse pipeline of clinical and pre-clinical drug candidates, addressing significant unmet medical needs in skin disorders. Notable products in its portfolio include CT327, a TrkA kinase inhibitor aimed at treating psoriasis and atopic dermatitis; CT340, which targets both TrkA and MAP2K3 kinases for inflammatory arthritis and pain; and CT637, an HMGB1 antagonist for various inflammatory conditions. Creabilis also engages in early-stage projects to explore additional treatment options. With research offices in Ivrea, Italy, and development operations in Canterbury, United Kingdom, the company aims to market its innovative therapies either independently or through partnerships.
MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.
DBV Technologies S.A. is a clinical-stage biopharmaceutical company based in Montrouge, France, dedicated to developing epicutaneous immunotherapy products aimed at treating food allergies. The company's lead candidate, Viaskin Peanut, has completed Phase III clinical trials for peanut allergies in children and adults. Additionally, DBV is developing Viaskin Milk, currently in Phase I/II trials for cow's milk protein allergy and related conditions, and Viaskin Egg, which is in pre-clinical stages for hen's egg allergy. The company also works on a booster vaccine for Bordetella pertussis and has earlier-stage research programs targeting respiratory syncytial virus, Crohn's disease, celiac disease, and type I diabetes. DBV Technologies collaborates with Nestlé Health Science to create MAG1C, a diagnostic patch test for non-IgE mediated cow's milk protein allergy in infants and toddlers. Founded in 2002, the company aims to provide safe and effective treatments for food allergies through its innovative Viaskin technology platform, which delivers biologically active compounds via the skin to activate the immune system.
TME Pharma is a biotechnology company based in Berlin, Germany, focused on developing innovative therapeutics for cancer treatment. The company utilizes its proprietary Spiegelmer platform, which involves biostable aptamers and mirror image nucleic acids, to create a pipeline of clinical-stage product candidates. Its lead drug candidate, NOX-A12, is being investigated as a combination therapy for various cancer types, including metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. TME Pharma is also advancing NOX-E36, which has completed Phase IIa trials for diabetic nephropathy. The company has established partnerships, including a collaboration with Merck & Co. to explore the efficacy of NOX-A12 in combination with Keytruda in patients with metastatic solid tumors. Founded in 1997, TME Pharma continues to advance its mission of developing novel treatments for serious medical conditions.